SCHEMBL4033271

SCHEMBL4033271

CN(CCO)S(=O)(=O)c1cccc(Cl)c1Cl

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MCOLN3 Q8TDD5 1/20 0.55
GSTO1 P78417 1/20 0.49
BDKRB1 P46663 1/20 0.43
HSD11B1 P28845 1/20 0.42
ALDH1A1 P00352 4/20 0.41
KMT2A Q03164 3/20 0.40
RXFP1 Q9HBX9 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
TSHR P16473 1/20 0.40
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
CCR4 P51679 3/20 0.38
PTGES2 Q9H7Z7 1/20 0.38
SGK1 O00141 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4031734 0.87 GSTO1 (0.54) MCOLN3GSTO1HSD11B1ALDH1A1KMT2A
SCHEMBL7847967 0.86 MCOLN3 (0.56) MCOLN3GSTO1BDKRB1HSD11B1ALDH1A1
SCHEMBL12010352 0.86 MCOLN3 (0.56) MCOLN3BDKRB1HSD11B1ALDH1A1KMT2A
SCHEMBL3439979 0.84 MCOLN3 (0.55) MCOLN3GSTO1BDKRB1HSD11B1ALDH1A1
SCHEMBL4033897 0.82 GSTO1 (0.46) MCOLN3GSTO1BDKRB1HSD11B1ALDH1A1
SCHEMBL5383623 0.82 MCOLN3 (0.52) MCOLN3BDKRB1HSD11B1ALDH1A1KMT2A
SCHEMBL15314381 0.82 MCOLN3 (0.52) MCOLN3BDKRB1HSD11B1ALDH1A1KMT2A
SCHEMBL5111158 0.81 MCOLN3 (0.52) MCOLN3GSTO1BDKRB1HSD11B1ALDH1A1
SCHEMBL5393186 0.80 MCOLN3 (0.51) MCOLN3GSTO1BDKRB1HSD11B1ALDH1A1
SCHEMBL5115197 0.80 MCOLN3 (0.51) MCOLN3GSTO1BDKRB1HSD11B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521744-B1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS FOURNIER LAB SA (FR) 2009-04-01 EP disclosed
US-7361687-B2 Arylsulphonamide derivatives and methods of preparing LABORATOIRES FOURNIER SA (FR) 2008-04-22 US disclosed
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents LABORATOIRES FOURNIER SA (FR) 2006-04-20 US disclosed
EP-1521744-A1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS LABORATOIRES FOURNIER S.A. (FR) 2005-04-13 EP disclosed
WO-2003106428-A1 NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS LABORATOIRES FOURNIER SA (FR) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents UGT1A1, UGT2B7, UGT1A6 MCOLN3 4434/4885GSTO1 392/4885BDKRB1 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.